NEJM March 5 2026 Finerenone in Type 1 Diabetes and Chronic Kidney Disease

This clinical study investigates whether the drug finerenone can help protect the kidneys of adults living with type 1 diabetes, a population for whom the medication's effects were previously uncertain. By tracking the urinary albumin-to-creatinine ratio, researchers discovered that those taking the drug experienced a significant reduction in protein leakage compared to those on a placebo. While the treatment proved effective at lowering this key marker of kidney damage, it also carried a higher risk of hyperkalemia, or elevated potassium levels. Ultimately, the trial demonstrates that this nonsteroidal therapy offers a promising new intervention for managing chronic kidney disease in patients with type 1 diabetes